Blood Clot Risk from COVID-19 Higher than After Vaccines: Study
Blood Clot Risk from COVID-19 Higher than After Vaccines: Study
The chance of developing cerebral venous sinus thrombosis was nearly 10 times higher in the two weeks following a diagnosis of SARS-CoV-2 infection than after receiving an mRNA vaccine, a data analysis finds.
Blood Clot Risk from COVID-19 Higher than After Vaccines: Study
Blood Clot Risk from COVID-19 Higher than After Vaccines: Study

The chance of developing cerebral venous sinus thrombosis was nearly 10 times higher in the two weeks following a diagnosis of SARS-CoV-2 infection than after receiving an mRNA vaccine, a data analysis finds.

The chance of developing cerebral venous sinus thrombosis was nearly 10 times higher in the two weeks following a diagnosis of SARS-CoV-2 infection than after receiving an mRNA vaccine, a data analysis finds.

AstraZeneca
US Health Authorities Ask for Pause in J&J COVID-19 Vaccination
US Health Authorities Ask for Pause in J&J COVID-19 Vaccination
Kerry Grens | Apr 13, 2021
The FDA and CDC are investigating a handful of reports of blood clots that occurred several days after people received the one-and-done shot.
Blood Clots a Very Rare Side Effect of AstraZeneca Vaccine: EMA
Blood Clots a Very Rare Side Effect of AstraZeneca Vaccine: EMA
Catherine Offord | Apr 8, 2021
The European Medicines Agency emphasizes that the benefits of the jab in protecting against COVID-19 still far outweigh the risks.
AstraZeneca’s COVID-19 Shot Completely Prevented Severe Disease
AstraZeneca’s COVID-19 Shot Completely Prevented Severe Disease
Kerry Grens | Mar 22, 2021
The vaccine was 79 percent effective at blocking symptomatic infections, according to data from a Phase 3 trial in the US, Chile, and Peru. A US safety oversight board says the data might be incomplete.
José Baselga, Renowned Oncologist, Dies at 61
José Baselga, Renowned Oncologist, Dies at 61
Asher Jones | Mar 22, 2021
The cancer researcher and executive vice president of AstraZeneca’s oncology research and development is well known for his role in the development of pivotal breast cancer therapies.
Oxford/AstraZeneca COVID-19 Vaccine on Hold in Some Countries
Oxford/AstraZeneca COVID-19 Vaccine on Hold in Some Countries
Asher Jones | Mar 12, 2021
Rollouts of the shot have ground to a halt following reports of blood clots, but health authorities say that these fears are unfounded and vaccination programs should continue.
COVID-19 Vaccine Combos Aim to Boost Immunity
COVID-19 Vaccine Combos Aim to Boost Immunity
Asher Jones | Mar 9, 2021
Mix-and-match shots could simplify vaccine rollout and stimulate more-robust immune responses. Ongoing clinical trials will soon give answers.
COVID-19 Hospitalizations Tank a Month After Vaccines Roll Out
COVID-19 Hospitalizations Tank a Month After Vaccines Roll Out
Asher Jones | Feb 23, 2021
Two preliminary reports from the UK provide real-world evidence in support of the Pfizer/BioNTech and Oxford-AstraZeneca vaccines.
COVID-19 Vaccine Trial Pauses After Adverse Reaction
COVID-19 Vaccine Trial Pauses After Adverse Reaction
Amanda Heidt | Sep 9, 2020
The hold will likely delay trial results, and scientists say the pause is proof that safety protocols in clinical trials are working as they should.
PARP Inhibitors Are Improving the Outlook of Hard-to-Treat Cancers
PARP Inhibitors Are Improving the Outlook of Hard-to-Treat Cancers
Vicki Brower | Apr 1, 2018
With three recent FDA approvals, and a number of Phase 3 trials ongoing, the drugs are seeing a surge in interest.
AstraZeneca Downsizing R&D Staff
AstraZeneca Downsizing R&D Staff
Kate Yandell | Mar 19, 2013
Positions for 1,600 scientists at the pharmaceutical company will be eliminated globally.